Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$1.49 USD
+0.04 (2.76%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.47 -0.02 (-1.34%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Werewolf Therapeutics, Inc.'s return on equity, or ROE, is -111.87% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that HOWL has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
HOWL 1.49 +0.04(2.76%)
Will HOWL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HOWL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOWL
Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
HOWL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Other News for HOWL
180 Bullish Setup appears for HOWL after 2.76% move
Is HOWL building bullish momentum? Pocket Pivot shows up after advancing 3.57%
Bollinger Band Squeeze appears for HOWL after 3.45% move
H.C. Wainwright Sticks to Its Buy Rating for Werewolf Therapeutics (HOWL)
HOWL forms 180 Bullish Setup on September 16